News
Men with gout and obesity receiving febuxostat-based ULT were less likely to achieve SU targets and more frequently experienced disease flares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback